Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild type metastatic colorectal cancer in the CAPRI 2-GOIM trial
D Ciardiello,L B Bielo,S Napolitano,E Martinelli,T Troiani,A Nicastro,T P Latiano,P Parente,E Maiello,A Avallone,N Normanno,S Pisconti,C Nisi,R Bordonaro,A E Russo,E Tamburrini,I Toma,C Lotesoriere,S Vallarelli,M G Zampino,N Fazio,G Curigliano,F De Vita,F Ciardiello,G Martini,CAPRI-2 GOIM study Group.,Davide Ciardiello,Luca Boscolo Bielo,Stefania Napolitano,Erika Martinelli,Teresa Troiani,Antonella Nicastro,Tiziana Pia Latiano,Paola Parente,Evaristo Maiello,Antonio Avallone,Nicola Normanno,Salvatore Pisconti,Claudia Nisi,Roberto Bordonaro,Alessia Erika Russo,Emiliano Tamburrini,Ilaria Toma,Claudio Lotesoriere,Simona Vallarelli,Maria Giulia Zampino,Nicola Fazio,Giuseppe Curigliano,Fortunato Ciardiello,Giulia Martini,Sara Lonardi,Chiara Cremolini,Carlo Garufi,Pierosandro Tagliaferri,Giampaolo Tortora,Filippo Pietrantonio,Antonio Febbraro,Gerardo Rosati,Silvana Leo,Oronzo Brunetti,Rosanna Berardi,Saverio Cinieri,Mario Scartozzi,Alberto Zaniboni,Giancarlo Paoletti
DOI: https://doi.org/10.1016/j.annonc.2024.08.2334
2024-08-28
Abstract:Background: Emerging evidence supports tumor tissue-based comprehensive genomic profiling (CGP) in metastatic colorectal cancer (mCRC). Data on liquid biopsy-based circulating tumor DNA (ctDNA) CGP are scarce and mainly retrospective. Prospective comparison between the two tests is not currently available. Methods: The CAPRI 2-GOIM trial investigates efficacy and safety of ctDNA-driven, cetuximab-based, sequence of three treatment lines in patients with RAS/BRAFV600E wild type (WT) mCRC, as determined by local laboratory. Before first-line therapy, CGP is performed with FoundationOne (F1) CDx and F1 Liquid (F1L) CDx (324 genes) on tumor tissue DNA and plasma ctDNA, respectively. Results: For 2/207 (0.96%) patients, no ctDNA was detected by F1L CDx. No patient displayed tumor fraction (TF) below 1%, whereas elevated ctDNA (TF≥10%) was detected among 140/205 (68.3%) patients. 1013 genomic variants were identified. F1L CDx found KRAS, NRAS or BRAFV600E alterations in 19 patients, whose tumors were classified as RAS/BRAFV600E WT by local laboratory. Both F1 CDx and F1L CDx were available for 164/205 (80%) patients. Concordance of 61.4% between the two tests was observed. Concordance increased to 72.7% for F1L CDx with TF ≥10%. Concordance for genes potentially involved in anti-epidermal growth factor receptor (EGFR) resistance was found in 137/164 (83%) patients, increasing to 91.5% for F1L CDx with TF ≥10%. A higher number of genomic alterations was detected by F1L CDx compared with F1 CDx, including 6 cases with KRAS and NRAS alterations. Overall, 109/205 (53.2%) patients displayed at least one actionable genomic alteration (I to IIIB), according to the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT). Conclusion: Baseline liquid biopsy-based CGP is feasible, it has high concordance with tumor tissue-based CGP, it could better recapitulate tumor heterogeneity, and it is clinically informative by identifying additional actionable genomic alterations in approximately half of RAS/BRAFV600E WT mCRC patients.